Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial-Reference-Cited by-同舟云学术

Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial

Published:2023-09 Issue:9 Volume:23 Page:1062-1071
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Wilkinson Amanda L,Zaman Khalequ,Hoque Masuma,Estivariz Concepcion F,Burns Cara C,Konopka-Anstadt Jennifer L,Mainou Bernardo A,Kovacs Stephanie D,An Qian,Lickness Jacquelyn S,Yunus Mohammad,Snider Cynthia J,Zhang Yiting,Coffee Elizabeth,Abid Talha,Wassilak Steven G F,Pallansch Mark A,Oberste M Steven,Vertefeuille John F,Anand Abhijeet

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference30 articles.

1. Global eradication of poliovirus: history and rationale;Dowdle,2002

2. Progress toward polio eradication—worldwide, January 2020–April 2022;Rachlin;MMWR Morb Mortal Wkly Rep,2022

3. Poliovirus vaccine—live;Sutter,2012

4. Optimal schedule for the administration of oral poliovirus vaccine;Patriarca,1993

5. Viral vaccination via the mucosal routes;Ogra;Rev Infect Dis,1980

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization;Vaccine;2024-01

2. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study;The Lancet Infectious Diseases;2024-01

3. Surveillance of Wastewater Bodies from Bannu, Khyber Pakhtunkhwa, Pakistan for Poliovirus;BioScientific Review;2023-12-05

4. Novel oral polio vaccine for serotype 2: new hope;The Lancet Infectious Diseases;2023-12

5. Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic;The Lancet Infectious Diseases;2023-12